Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: Management-Reference-Cited by-同舟云学术

Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: Management

Published:2017-12-28 Issue:1 Volume:33 Page:30-36
ISSN:0815-9319
Container-title:Journal of Gastroenterology and Hepatology
language:en
Short-container-title:Journal of Gastroenterology and Hepatology

Author:

Park Dong Il¹,Hisamatsu Tadakazu²,Chen Minhu³,Ng Siew Chien⁴,Ooi Choon Jin⁵,Wei Shu Chen⁶,Banerjee Rupa⁷,Hilmi Ida Normiha⁸,Jeen Yoon Tae⁹,Han Dong Soo¹⁰,Kim Hyo Jong¹¹,Ran Zhihua¹²,Wu Kaichun¹³,Qian Jiaming¹⁴,Hu Pin-Jin³,Matsuoka Katsuyoshi¹⁵,Andoh Akira¹⁶,Suzuki Yasuo¹⁷,Sugano Kentaro¹⁸,Watanabe Mamoru¹⁵,Hibi Toshifumi¹⁹,Puri Amarender S²⁰,Yang Suk-Kyun²¹

Affiliation:

1. Department of Internal Medicine; Kangbuk Samsung Hospital Sungkyunkwan University; Seoul Korea

2. The Third Department of Internal Medicine; Kyorin University School of Medicine; Tokyo Japan

3. Department of Gastroenterology, The First Affiliated Hospital; Sun Yat-sen University; Guangzhou China

4. Department of Medicine and Therapeutics, Institute of Digestive Disease, LKS Institute of Health Science, State Key Laboratory of Digestive Disease; The Chinese University of Hong Kong; Hong Kong

5. Gleneagles Medical Centre and Duke-NUS Medical School; Singapore

6. Department of Internal Medicine; National Taiwan University Hospital and College of Medicine; Taipei Taiwan

7. Department of Medical Gastroenterology; Asian Institute of Gastroenterology; Hyderabad India

8. Department of Medicine; University of Malaya; Kuala Lumpur Malaysia

9. Department of Internal Medicine; Korea University; Seoul Korea

10. Department of Internal Medicine; Hanyang University Guri Hospital; Seoul Gyunggi Korea

11. Department of Internal Medicine; Kyung Hee University; Seoul Korea

12. Department of Gastroenterology; Shanghai Jiao Tong University; Shanghai China

13. Department of Gastroenterology; Fourth Military Medical University; Xi'an China

14. Department of Gastroenterology; Peking Union Medical College; Beijing China

15. Department of Gastroenterology and Hepatology; Tokyo Medical and Dental University; Tokyo Japan

16. Department of Gastroenterology; Shiga University; Otsu Japan

17. Department of Internal Medicine; Toho University; Sakura Japan

18. Department of Medicine; Jichi Medical University; Tochigi Japan

19. Center for Advanced IBD Research and Treatment; Kitasato University; Tokyo Japan

20. Department of Gastroenterology; GB Pant Institute of Postgraduate Medical Education and Research; New Delhi India

21. Department of Gastroenterology; University of Ulsan College of Medicine, Asan Medical Center; Seoul Korea

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jgh.14018/fullpdf

Reference65 articles.

1. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent;Keane;N. Engl. J. Med.,2001

2. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report;Gomez-Reino;Arthritis Rheum.,2003

3. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies;Souto;Rheumatology (Oxford),2014

4. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance;Cantini;J. Rheumatol. Suppl.,2014

5. Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials;Lorenzetti;Ann. Med.,2014

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tuberculosis risk in patients with Crohn’s disease on biologics: a retrospective analysis of the Japanese Medical Claims Database;Intestinal Research;2024-08-19

2. Microbiota-Induced Epigenetic Alterations in Depressive Disorders Are Targets for Nutritional and Probiotic Therapies;Genes;2023-12-14

3. Asia‐Pacific's first position papers on pediatric inflammatory bowel disease: Tackling unique challenges in the region;Journal of Gastroenterology and Hepatology;2023-04

4. Management and monitoring of pediatric inflammatory bowel disease in the Asia‐Pacific region: A position paper by the Asian Pan‐Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group: Surgical management, disease monitoring, and special considerations;Journal of Gastroenterology and Hepatology;2023-01-13

5. The treatment of inflammatory bowel disease with monoclonal antibodies in Asia;Biomedicine & Pharmacotherapy;2023-01